Daan Jan Willem Rauwerdink

Mr. Daan Jan Willem Rauwerdink

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
DRDaan Jan Willem Rauwerdink
Daan Jan Willem Rauwerdink
ONOlivier Jules van Not
Olivier Jules van Not
MMMelissa de Meza
Melissa de Meza
RDRemco van Doorn
Remco van Doorn
JHJos van der Hage
Jos van der Hage
Ellen KapiteijnEllen Kapiteijn
Ellen Kapiteijn
Introduction: The difference in incidence and severity of anti-PD-1 therapy-related adverse events (irAEs) between adjuvant and advanced treated melanoma patients remains unclear, as no head-to-head studies have compared these groups. Methods: This multi-center cohort study analyzed melanoma patients treated with anti-PD-1 in adjuvant or advanced settings between 2015 and 2021. Comorbidities and ECOG performance status were assessed before treatment, and grade III-IV irAEs were monitored during treatment. Univariate and multivariate regression analyses were conducted to identify factors associated with irAE development. Results: A total of 1465 advanced melanoma patients and 908 resected melanoma patients received anti-PD-1 therapy. Adjuvant-treated patients were younger, with a median age of 63 years compared to 69 years in the advanced group (p < 0.01), and had a better ECOG performance status (p < 0.01). Comorbidities were seen more frequently in advanced melanoma patients than in those receiving adjuvant treatment, 76% versus 68% (p < 0.01). Grade III-IV irAEs occurred in 214 (15%) advanced treated patients and in 119 (13%) adjuvant-treated patients. Multivariate analysis showed an increased risk of severe irAE development with the presence of any comorbidity (adjusted OR 1.22, 95% CI 1.02–1.44) and ECOG status greater than 1 (adjusted OR 2.00, 95% CI 1.20–3.32). Adjuvant therapy was not associated with an increased risk of irAE development compared to advanced treatment (adjusted OR 0.95, 95% CI 0.74–1.21) after correcting for comorbidities and ECOG performance score. Anti-PD-1 therapy was halted due to toxicity (any grade irAE) more often in the adjuvant setting than in the advanced setting, 20% versus 15% (p < 0.01). Conclusions: Higher ECOG performance status and presence of any comorbidity were independently associated with an increased risk of Grade III-IV irAE in adjuvant and advanced treated melanoma patients. Patients treated in the adjuvant setting did not have an increased risk of developing severe irAEs compared to advanced melanoma patients. These findings are of clinical significance in consulting patients for adjuvant anti-PD-1 treatment.

19 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
DRDaan Jan Willem Rauwerdink
Daan Jan Willem Rauwerdink
RDRemco van Doorn
Remco van Doorn
JHJos van der Hage
Jos van der Hage
AEAlfonsus J. M. Van Den Eertwegh
Alfonsus J. M. Van Den Eertwegh
JHJohn B. A. G. Haanen
John B. A. G. Haanen
Ellen KapiteijnEllen Kapiteijn
Ellen Kapiteijn
Nodular melanoma (NM) is associated with a higher locoregional and distant recurrence rate compared with superficial spreading melanoma (SSM); it is unknown whether the efficacy of systemic therapy is limited. Here, we compare the efficacy of immunotherapy and BRAF/MEK inhibitors (BRAF/MEKi) in advanced NM to SSM. Patients with advanced stage IIIc and stage IV NM and SSM treated with anti-CTLA-4 and/or anti-PD-1, or BRAF/MEKi in the first line, were included from the prospective Dutch Melanoma Treatment Registry. The primary objectives were distant metastasis-free survival (DMFS) and overall survival (OS). In total, 1086 NM and 2246 SSM patients were included. DMFS was significantly shorter for advanced NM patients at 1.9 years (CI 95% 0.7–4.2) compared with SSM patients at 3.1 years (CI 95% 1.3–6.2) (p < 0.01). Multivariate survival analysis for immunotherapy and BRAF/MEKi demonstrated a hazard ratio for immunotherapy of 1.0 (CI 95% 0.85–1.17) and BRAF/MEKi of 0.95 (CI 95% 0.81–1.11). A shorter DMFS for NM patients developing advanced disease compared with SSM patients was observed, while no difference was observed in the efficacy of systemic immunotherapy or BRAF/MEKi between NM and SSM patients. Our results suggests that the worse overall survival of NM is mainly driven by propensity of metastatic outgrowth of NM after primary diagnosis.

17 August 2023 in New England Journal of Medicine
Verified
Journal Article
Closed access
DRDaan Jan Willem Rauwerdink
Daan Jan Willem Rauwerdink
DBDeepak Balak
Deepak Balak

19 February 2026 in JAAD Case Reports
Verified
Journal Article
Open access
DRDaan Jan Willem Rauwerdink
Daan Jan Willem Rauwerdink
RMRutger Casimir Melchers
Rutger Casimir Melchers
KQKoen D. Quint
Koen D. Quint
ANAnh Ly Nguyen
Anh Ly Nguyen
DBDeepak M.W. Balak
Deepak M.W. Balak

11 September 2024
Verified
Journal Article
Closed access
DRDaan Jan Willem Rauwerdink
Daan Jan Willem Rauwerdink
TRThijs Ruiken
Thijs Ruiken
DBDeepak M W Balak
Deepak M W Balak